Aim: To investigate the factors affecting (18)F FDOPA uptake in patients with primary brain tumors (PBT) after treatment.
Materials And Methods: 97 patients with PBT (6 were grade I, 40 were grade II, 29 were grade III and 22 were grade IV) underwent (18)F FDOPA positron emission tomography/computed tomography (PET/CT) after treatment. Intervals from surgery, chemotherapy (CHT) and radiotherapy (RT) were 41.48 (±42.27), 16.04 (±29.08) and 28.62 (±34.49) months respectively.
Results: (18)F FDOPA uptake in the site of recurrence was not related to the interval from surgery and CHT while a significant relationship has been found with the interval from RT and tumor grade.
Conclusions: The results of our study show that the interval from RT and the grade of PBT should be considered carefully when evaluating brain PET/CT scans since these factors could directly affect (18)F FDOPA uptake.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.nucmedbio.2015.01.002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparison of Ga-DOTANOC and F-FDOPA PET/CT for Detection of Recurrent or Metastatic Paragangliomas.
Radiol Imaging Cancer
January 2025
From the Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, 270 Dongan Road, Xuhui District, 200032 Shanghai, China; and Shanghai Engineering Research Center of Molecular Imaging Probes, Shanghai, China.
Purpose To evaluate the diagnostic performance of gallium 68 (Ga)-DOTA-NaI3-octreotide (Ga-DOTANOC) and fluorine 18 (F)-fluoro-l-3,4-dihydroxyphenylalanine (F-FDOPA) PET/CT in detecting recurrent or metastatic paragangliomas. Materials and Methods This single-center retrospective study included patients with paragangliomas who underwent both Ga-DOTANOC PET/CT and F-FDOPA PET/CT between August 2021 and December 2023. The diagnostic performance of these two tracers in detecting recurrent or metastatic tumors was compared using several metrics, including sensitivity, negative predictive value, and accuracy.
View Article and Find Full Text PDFShort-course hypofractionated proton beam therapy, incorporating F-DOPA PET and contrast-enhanced MRI targeting, for patients aged 65 years and older with newly diagnosed glioblastoma: a single-arm phase 2 trial.
Lancet Oncol
December 2024
Department of Radiation Oncology, Mayo Clinic, Rochester, MN, USA.
Background: Older patients (aged ≥65 years) with glioblastoma have a worse prognosis than younger patients and a median overall survival of 6-9 months. 3,4-Dihydroxy-6-[F]fluoro-L-phenylalanine (F-DOPA) PET sensitively and specifically identifies metabolically active glioblastoma for preferential targeting. Proton beam therapy potentially improves quality of life (QOL) by sparing more healthy brain tissue than photon radiotherapy.
View Article and Find Full Text PDFNeuroinflammation in Parkinson's disease: A study with [C]PBR28 PET and cerebrospinal fluid markers.
Parkinsonism Relat Disord
January 2025
Turku PET Centre, University of Turku, Turku, Finland; Division of Clinical Neurosciences, Turku University Hospital, Turku, Finland.
Objective: To investigate neuroinflammation in Parkinson's disease (PD) with [C]PBR28 positron emission tomography (PET) and cerebrospinal fluid (CSF) biomarkers, and the relationship to dopaminergic functioning measured with 6-[F]-fluoro-L-dopa ([F]FDOPA) PET.
Methods: The clinical cohort consisted of 20 subjects with PD and 51 healthy controls (HC). All HC and 15 PD participants underwent [C]PBR28 High Resolution Research Tomograph (HRRT) PET for the quantitative assessment of cerebral binding to the translocator protein (TSPO), a neuroinflammation marker.
Positron Emission Tomography Imaging of Pheochromocytoma and Paraganglioma-18F-FDOPA vs Somatostatin Analogues.
J Clin Endocrinol Metab
January 2025
Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus N DK-8200, Denmark.
Context: Functional imaging with positron emission tomography (PET) scans is an essential part of the diagnostic workup for pheochromocytoma and paraganglioma (PPGL). The purpose of this review is to (1) provide a brief overview of functional imaging for PPGL, (2) summarize selected present and older guideline and review recommendations, and (3) conduct a literature review on the diagnostic performance of the most used PET tracers for PPGL.
Evidence Acquisition: We conducted a systematic literature search in PubMed from January 2004 to August 2024 with the search string ("Pheochromocytoma" OR "Paraganglioma") AND ("Positron Emission Tomography" OR "Radionuclide Imaging" OR ("PET" AND ("FDG" OR "DOTATOC" OR "DOTANOC" OR "DOTATATE" OR "DOPA" OR "FDOPA"))).
Update on the Role of [F]FDOPA PET/CT.
Semin Nucl Med
November 2024
Department of Nuclear Medicine and Molecular Imaging, Medical Imaging Center, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
[F]-dihydroxyphenylalanine ([F]FDOPA) is a radiopharmaceutical used in a broad spectrum of diseases, including neuroendocrine tumors (NETs), congenital hyperinsulinism, parkinsonian syndromes and neuro-oncology. Genetic analysis and disease specific biomarkers may guide the optimum selection of patients that may benefit most from [F]FDOPA PET in different stages of several neuroendocrine neoplasms and in congenital hyperinsulinism. For clinical routine in neuro-oncology, indications for [F]FDOPA PET include tumor delineation and distinguishing between treatment related changes and recurrent disease.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!